Status:
COMPLETED
Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Parkinson Disease
Parkinson Disease Dementia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of mo...
Detailed Description
This is a single-site non-randomized open label clinical trial in patients with Parkinson disease (PD) and mild to moderate cognitive deficits, designed to 1) identify associations between cognitive i...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Diagnosis of idiopathic Parkinson disease.
- Mild to moderate cognitive impairment, as determined by a MoCA score of ≤ 25 and ≥ 10.
- Patient passes the Evaluation to Sign Consent (ESC) or a legally authorized representative (LAR) is present at the time of enrollment and signs the informed consent form on behalf of the patient.
- Patient is enrolled (or willing to be enrolled) in the University of Maryland Parkinson Disease and Movement Disorders Center PD Research Database (HP 42195)
Exclusion
- Advanced Parkinson disease (Hoehn \& Yahr stage 5), with inability to walk unassisted.
- Other medical condition(s) that significantly interfere(s) with gait and balance (e.g., advanced arthritis).
Key Trial Info
Start Date :
May 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03840837
Start Date
May 2 2019
End Date
April 1 2020
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland School of Medicine, Dept. of Neurology
Baltimore, Maryland, United States, 21201